// App-Quantinova.ai

515 : Phase 1 Study of Carfilzomib in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Researchers

Presenter

  • Attaphol Pawarode

Principal Investigators

  • Daniel R. Couriel

  • Thomas Braun

  • John M Magenau

  • Mary M Riwes

  • Brian L Parkin

  • Vedran Radojcic

  • David Frame

  • Sung Won Choi

  • Pavan Reddy

  • Steven C Goldstein

Medical Centers

  • College of Pharmacy, University of Michigan, Ann Arbor, MI

  • Division of Hematology, The University of Utah, Salt Lake City, UT

  • Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI

  • Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI

  • Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hematological malignancies

Biomarkers

  • Circulating tumor cells

  • Granulocyte colony-stimulating factor

Drug/Treatment

  • carfilzomib Intravenous

  • fludarabine tablet

  • Filgrastim

  • Tacrolimus

Outcome

  • N/A

Study Design

  • fixed dose

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved